MX2019001587A - Terapia de combinacion para enfermedad pulmonar obstructiva cronica (epoc). - Google Patents

Terapia de combinacion para enfermedad pulmonar obstructiva cronica (epoc).

Info

Publication number
MX2019001587A
MX2019001587A MX2019001587A MX2019001587A MX2019001587A MX 2019001587 A MX2019001587 A MX 2019001587A MX 2019001587 A MX2019001587 A MX 2019001587A MX 2019001587 A MX2019001587 A MX 2019001587A MX 2019001587 A MX2019001587 A MX 2019001587A
Authority
MX
Mexico
Prior art keywords
copd
combination therapy
formoterol
moderate
prevention
Prior art date
Application number
MX2019001587A
Other languages
English (en)
Inventor
Scuri Mario
Coli Pierfrancesco
Delmonte Giuseppe
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2019001587A publication Critical patent/MX2019001587A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
    • A61M16/20—Valves specially adapted to medical respiratory devices

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con formulaciones en aerosol que comprenden bromuro de glicopirronio, formoterol o una sal del mismo, y dipropionato de beclometasona que son útiles para la prevención o tratamiento de enfermedad pulmonar obstructiva crónica moderada/grave.
MX2019001587A 2016-08-17 2017-08-17 Terapia de combinacion para enfermedad pulmonar obstructiva cronica (epoc). MX2019001587A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16184608 2016-08-17
PCT/EP2017/070850 WO2018033598A1 (en) 2016-08-17 2017-08-17 Combination therapy for copd

Publications (1)

Publication Number Publication Date
MX2019001587A true MX2019001587A (es) 2019-07-04

Family

ID=56740118

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001587A MX2019001587A (es) 2016-08-17 2017-08-17 Terapia de combinacion para enfermedad pulmonar obstructiva cronica (epoc).

Country Status (30)

Country Link
US (1) US10098837B2 (es)
EP (1) EP3500241B1 (es)
JP (1) JP7384666B2 (es)
KR (1) KR102440850B1 (es)
CN (1) CN109562061A (es)
AU (1) AU2017314153B2 (es)
BR (1) BR112019003173A2 (es)
CA (1) CA3029481A1 (es)
DK (1) DK3500241T3 (es)
EA (1) EA201990514A1 (es)
ES (1) ES2961242T3 (es)
FI (1) FI3500241T3 (es)
GE (1) GEP20227418B (es)
HR (1) HRP20231729T1 (es)
HU (1) HUE064623T2 (es)
IL (1) IL264612B2 (es)
LT (1) LT3500241T (es)
MA (1) MA45984B1 (es)
MD (1) MD3500241T2 (es)
MX (1) MX2019001587A (es)
NZ (1) NZ750214A (es)
PH (1) PH12019500315A1 (es)
PL (1) PL3500241T3 (es)
PT (1) PT3500241T (es)
RS (1) RS64751B1 (es)
SG (1) SG11201900471VA (es)
SI (1) SI3500241T1 (es)
UA (1) UA123231C2 (es)
WO (1) WO2018033598A1 (es)
ZA (1) ZA201900239B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
KR101757951B1 (ko) * 2009-12-23 2017-07-13 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 조합요법
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD
CN112438966B (zh) * 2019-08-30 2022-08-26 四川普锐特药业有限公司 一种医用定量吸入气雾剂
PE20221439A1 (es) * 2019-12-02 2022-09-21 Chiesi Farm Spa Lata de acero inoxidable para inhaladores dosificadores presurizados
US20230347080A1 (en) * 2020-01-28 2023-11-02 Chiesi Farmaceutici S.P.A Pressured metered dose inhalers comprising a buffered pharmaceutical formulation
CN115087431A (zh) * 2020-02-20 2022-09-20 奇斯药制品公司 包含缓冲药物制剂的加压定量吸入器
EP4188327A1 (en) 2020-07-31 2023-06-07 Chemo Research, S.L. Combination therapy for inhalation administration
US20230277451A1 (en) * 2020-10-09 2023-09-07 Chiesi Farmaceutici S.P.A. A pharmaceutical formulation for pressurised metered dose inhaler

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
IT1317720B1 (it) 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
ME00220B (me) 2000-05-22 2010-10-10 Chiesi Farm Spa Stabilne farmaceutske formulacije rastvora za inhalatore odmjerene doze pod pritiskom
EP1321159A1 (en) 2001-12-21 2003-06-25 CHIESI FARMACEUTICI S.p.A. Pressurized metered dose inhaler (pMDI) actuators with laser drilled orifices
EP1713473B1 (en) 2004-02-06 2013-03-13 MEDA Pharma GmbH & Co. KG The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
MX2007012084A (es) 2005-03-30 2007-11-21 Schering Corp Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada.
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
KR101757951B1 (ko) 2009-12-23 2017-07-13 키에시 파르마슈티시 엣스. 피. 에이. Ｃｏｐｄ용 조합요법
CN104582771B (zh) 2012-08-29 2018-09-04 奇斯药制品公司 气溶胶吸入装置
JP2016519160A (ja) 2013-05-22 2016-06-30 パール セラピューティクス，インコーポレイテッド ３つ以上の活性薬剤を呼吸性送達するための組成物、方法、及びシステム
LT3096737T (lt) * 2013-12-30 2018-06-11 Chiesi Farmaceutici S.P.A. Stabili glikopironio bromido ir formoterolio derinio suspausto aerozolio tirpalo kompozicija
EP3384898A1 (en) * 2013-12-30 2018-10-10 Chiesi Farmaceutici S.p.A. Stable pressurised aerosol solution composition of glycopyrronium bromide and formoterol combination
US10098837B2 (en) 2016-07-28 2018-10-16 Chiesi Farmaceutici S.P.A. Combination therapy for COPD

Also Published As

Publication number Publication date
FI3500241T3 (fi) 2023-12-15
SG11201900471VA (en) 2019-03-28
ES2961242T3 (es) 2024-03-11
AU2017314153B2 (en) 2023-06-01
WO2018033598A1 (en) 2018-02-22
IL264612A (en) 2019-02-28
LT3500241T (lt) 2023-11-10
EA201990514A1 (ru) 2019-07-31
MA45984B1 (fr) 2023-11-30
EP3500241A1 (en) 2019-06-26
MA45984A (fr) 2021-04-28
CN109562061A (zh) 2019-04-02
NZ750214A (en) 2020-07-31
US10098837B2 (en) 2018-10-16
AU2017314153A1 (en) 2019-02-07
PT3500241T (pt) 2023-10-24
JP2019528316A (ja) 2019-10-10
HUE064623T2 (hu) 2024-04-28
PL3500241T3 (pl) 2024-03-11
MD3500241T2 (ro) 2024-03-31
GEP20227418B (en) 2022-09-26
ZA201900239B (en) 2020-05-27
BR112019003173A2 (pt) 2019-07-09
HRP20231729T1 (hr) 2024-03-15
SI3500241T1 (sl) 2024-02-29
CA3029481A1 (en) 2018-02-22
PH12019500315A1 (en) 2020-01-20
JP7384666B2 (ja) 2023-11-21
US20180028439A1 (en) 2018-02-01
EP3500241B1 (en) 2023-10-04
UA123231C2 (uk) 2021-03-03
DK3500241T3 (da) 2023-11-13
RS64751B1 (sr) 2023-11-30
IL264612B2 (en) 2023-02-01
KR102440850B1 (ko) 2022-09-07
KR20190039408A (ko) 2019-04-11
IL264612B (en) 2022-10-01

Similar Documents

Publication Publication Date Title
PH12019500315A1 (en) Combination therapy for copd
CY1123391T1 (el) (2s)-n-[(1s)-1-kyano-2-φainyλaιθyλ]-1,4-oξazeπan-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης ι
EP3600281A4 (en) COMBINATION THERAPY FOR TREATING OR PREVENTING TUMORS
PH12016501750A1 (en) Human plasma kallikrein inhibitors
SG10201913575VA (en) Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
MD20160138A2 (ro) Combinaţie
WO2015077503A8 (en) Autotaxin inhibitor compounds
PH12018502109A1 (en) Medicine obtained by combining fxr agonist and arb
IL273169A (en) A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
EP3697764A4 (en) GLUTAMINASE INHIBITOR THERAPY
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
IL248874A0 (en) Combinations of tiotropium bromide, formoterol and budesonide for the treatment of chronic obstructive pulmonary disease
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
EP3927328A4 (en) INHALED THERAPEUTIC
WO2016191363A8 (en) Combination hiv therapeutic
EP3835311C0 (en) NKX3.2 FRAGMENT AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS ACTIVE INGREDIENT
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
NZ733451A (en) Combination therapy for pulmonary hypertension
EP3727587A4 (en) COMPOSITIONS AND METHODS FOR THERAPY OF WILLIAMS SYNDROME (WS)
WO2016046414A3 (en) Cdc25a inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse
MA40027A (fr) Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique
EA029678B9 (ru) Четвертичные соли пиперидиния
PH12016501975A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
WO2016144706A3 (en) Autotaxin inhibitor compounds and uses thereof